drugset / Trial / NCT00839163
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for the anticipated phase III trials and for the future clinical use.
Timeline
- Start
- 2004-03
- Primary completion
- 2005-10
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Enoxaparin sodium | Other / unclassified | 1 mg/kg | Subcutaneous |
| Subject | Rivaroxaban | Other / unclassified | 10 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 20 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 30 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 40 mg | Oral |